Navigation Links
PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S.
Date:7/21/2008

Clinical study and limited launch in Italy continue

FRANKLIN, Mass., July 21 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC) announced today that it will defer the commencement of the U.S. pivotal trial of its RenalGuard(TM) System in the prevention of Contrast-Induced Nephropathy (CIN). The company continues to support the investigator-sponsored clinical trial now ongoing in Milan, Italy as well as the limited market launch of RenalGuard in Europe, which began in the first quarter of this year, both of which are focused on the CIN prevention market.

Mark R. Tauscher, President and Chief Executive Officer of PLC, said, "We are taking this action now because, while we have sufficient funds to commence the U.S. pivotal trial at this time, we believe we will be in a better position to successfully raise the funding necessary to complete the trial and prepare for U.S. market launch in the future, once we have the expected positive clinical data from the study currently underway in Italy at the Centro Cardiologico Monzino-University of Milan (CCM). For these reasons, after consultation with our lead U.S. investigators, we have elected to postpone the start of the U.S. pivotal trial. We anticipate that this deferral will reduce the expected increase in our research and development costs that we had previously estimated for the remainder of 2008, as we lower our expenses associated with clinical trial oversight and management."

Mr. Tauscher added, "In the meantime, we are continuing our dual commercialization strategy for RenalGuard. First and foremost, we are continuing to work with the U.S. Food and Drug Administration to secure a full approval of our RenalGuard study protocol so that we are well-positioned t
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
2. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
6. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
10. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
11. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 26 Paratek Pharmaceuticals, Inc. today,announced positive Phase ... a first-in-class aminomethylcycline (AMC). The Phase 2 study ... forms of PTK 0796 to,Zyvox(R) in the treatment ... (cSSSIs). Paratek,s trial met its primary safety and,tolerability ...
... affirmed the clinical benefits of,ACTEMRA -, NUTLEY, ... III studies,showed that patients who suffer from the ... significant improvements in signs and,symptoms when treated with ... with methotrexate alone. The final results of,both studies ...
Cached Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:8/22/2014)... Pirate Jonny's Caribbean BBQ Rubs, ... new recipe cards, fun t-shirts, and caps for consumers ... Clearwater, Florida, Pirate Jonny, aka, Jonathan Toner, founder, decided ... to three recipes featuring different flavors of the Caribbean, ... website. The recipe cards will feature "easy to ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Braverman Eye ... in Fort Lauderdale at the most affordable fee. They ... eyesight through their advanced Lasik treatments. LASIK is a ... the Braverman Eye Center has been delivering successful LASIK ... live a glasses-free and contact lenses-free life with the ...
(Date:8/22/2014)... Alzheimer,s disease can be slowed and some of ... is found in pomegranate. Also, the painful ... and Parkinson,s disease could be reduced, according to ... University of Huddersfield scientist Dr Olumayokun Olajide, who ... , Now, a new phase of research can ...
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... (HealthDay News) -- The U.S. Drug Enforcement Administration (DEA) ... containing hydrocodone, which has been tied to a surge ... new restrictions would cover prescription narcotic drugs such as ... the same regulatory class as painkillers such as Oxycontin, ... to a three-month supply of the drug and will ...
Breaking Medicine News(10 mins):Health News:Pirate Jonny's Caribbean BBQ Rubs, Seasonings & Sauces Get New Look by Hoisting New Recipe Card Creations and New Clothing Apparel for its Logos 2Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 2Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 3
... INDIANAPOLIS, July 1 CoLucid Pharmaceuticals, Inc., ... central nervous,system disorders, announced it closed a ... Capital led the round, which included previous ... Funds and,Triathlon Medical Ventures. The financing will ...
... Conn., July 1 The organic food that ... intended and often,contains more nutrients than its counterpart., ... the popularity of organic food on the rise, ... more accessible than ever., "The difference between ...
... USB duplicator with copy protection and digital rights management features available ... Only partitions, Autorun support, copy and paste restriction and document printing ... ... (PRWEB) July 1, 2008 -- Nexcopy Inc., a leading manufacturer in ...
... can be overwhelming; Allsup provides tips on getting prepared to file ... ... Every day, people across the United States must stop working because ... challenges when faced with these circumstances can be overwhelming, including where ...
... Researchers have developed a series of tests that for the ... and smell (olfactory function) in young children, according to a ... Otolaryngology Head and Neck Surgery . , The study, ... 5-7 can identify a majority of 16 different test odorants ...
... showing that psilocybin, a substance contained in "sacred mushrooms," ... that those beneficial effects appear to last more than ... of Psychopharmacology , the Johns Hopkins researchers note that ... controlled conditions in a Hopkins study published in 2006, ...
Cached Medicine News:Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 4Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 2Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 2Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 4Health News:Spiritual effects of hallucinogens persist, Johns Hopkins researchers report 2
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: